New cocktail of drugs and radiation takes on tough lung cancer
NCT ID NCT04728230
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of the PARP inhibitor olaparib, the immunotherapy durvalumab, chemotherapy (carboplatin and etoposide), and radiation in people with extensive-stage small cell lung cancer who haven't been treated yet. The goal is to see if this mix is safe and works better than current treatments. About 63 participants will be enrolled at M.D. Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (PARP inhibitor), durvalumab (immunotherapy), carboplatin, etoposide, and radiation therapy
What this could lead to
If successful, this combination could become a new standard first-line treatment for extensive-stage small cell lung cancer, potentially improving how long patients live without their cancer growing.
What could go wrong
This is an early-phase trial with only 63 participants, so results may not apply to all patients. Combining multiple treatments also raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States